All entries on ArisGlobal across all areas, newest first. tag:eurotrack.ai,2026:en:en/companies/arisglobal 2026-07-23T06:00:00Z Eurotrack tag:eurotrack.ai,2026:b1327aa4:en 2026-07-23T06:00:00Z

The 16 July reports became a deal: on 23 July 2026 Dassault Systèmes announced via press release a definitive agreement to acquire ArisGlobal — US$1.8bn in cash at closing plus up to US$200m contingent on multi-year AI-related revenue milestones. ArisGlobal runs an AI-native compliance platform for the life sciences industry with more than 200 customers (including half of the top 50 global biopharma companies), processes more than 12 million patient safety reports a year and employs over 1,300 people; 2026 revenue is projected at US$175m. Closing is expected in the second half of 2026 subject to regulatory approvals. It is the group's second-largest acquisition after Medidata (2019). — Source: https://www.3ds.com/newsroom/press-releases/dassault-systemes-acquire-arisglobal-creating-unified-ai-intelligence-platform-life-sciences-industry-connecting-molecule-patient-and-real-world-outcomes

tag:eurotrack.ai,2026:4baad49f:en 2026-07-16T06:00:00Z

Reported (first by the Financial Times, 16 July): Dassault Systèmes is in talks to buy US pharmacovigilance and clinical-trial software specialist ArisGlobal (~$200m revenue, ~1,300 employees) from Nordic Capital for about US$2bn. It would be the company's second-largest acquisition after Medidata (2019, $5.8bn); a deal is not certain. UPDATE (23 July 2026): Confirmed — Dassault Systèmes and ArisGlobal signed a definitive acquisition agreement (US$1.8bn plus up to US$200m earn-out); see the separate entry dated 23 July. — Source: https://live.euronext.com/en/financial-news/dassault-systemes-talks-buy-drug-trial-software-firm-arisglobal-ft-reports